DiaLife教育项目对成年糖尿病患者亲属的疗效——整群随机对照试验研究方案
本研究为整群随机对照试验,拟将研究中心随机分配至干预组或对照组,纳入1型和2型糖尿病患者的亲属及患者。干预组亲属参加DiaLife教育项目,对照组为等待名单对照,主要结局分别为亲属的糖尿病相关知识与患者的HbA1c值,并在干预后6个月和12个月评估长期疗效。
要点
- DiaLife是德国糖尿病护士与教育专家协会(VDBD)制定的首个专为糖尿病患者亲属设计的教育项目。
- 研究采用整群随机对照设计,以研究中心为单位随机分配至干预组或等待名单对照组。
- 主要结局为参与者的糖尿病相关知识和患者的HbA1c值,长期疗效在干预后6个月和12个月评估。
核心结论
- 研究结果将提供DiaLife教育项目疗效的信息,并识别可能阻碍亲属教育项目成功实施的因素。
研究设计与样本
- 整群随机对照试验,研究中心被随机分配至干预组或对照组。
- 研究中心招募1型和2型糖尿病患者的亲属及患者。
- 干预组亲属参加DiaLife教育项目,对照组为等待名单对照。
- 采用分层回归模型分析随时间变化的效应。
- 试验注册于德国临床试验注册中心(DRKS00015157),注册日期为2018年8月24日。
主要发现
- 原文未报告结果。
关键数值与推荐
- 参与者主要结局为糖尿病相关知识,比较干预组与对照组。
- 患者主要结局为HbA1c值。
- 次要结局包括糖尿病相关痛苦、家庭互动及其他次要终点。
- 长期疗效在干预后6个月和12个月评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The global prevalence of diabetes mellitus (DM) has been increasing over recent decades. In Germany, the prevalence for DM type 1 and type 2 in adults is estimated at about 7.7%. Hence, diabetes has to be classified as a serious public health concern. Being diagnosed with DM and facing possible sequelae might have a negative impact on patients' mental and physical well-being. However, diabetes not only affects patients themselves, but also their close relatives. To improve the quality of life for patients and relatives alike, the German Association of Diabetes Nurses and Education experts (VDBD) elaborated the first education program tailor-made for relatives of diabetes patients. This article describes the concept and design of the trial evaluating the efficacy of this education program called "DiaLife-Living Together with Diabetes". METHODS: This evaluation study is a cluster randomized controlled trial, in which the study centers will be randomly assigned either to the intervention group or the control group. Study centers will recruit relatives of and patients with DM type 1 and type 2. Members of the intervention group will participate in the education program DiaLife, whereas participants randomized in the control group will act as waiting-list controls. The study will assess the efficacy of DiaLife by comparing diabetes-related knowledge between the intervention and control groups as the primary outcome for participants. As the primary outcome in patients, the Hba1c value will be assessed. In addition, diabetes-related distress, family interaction, and other secondary endpoints will be considered as secondary outcomes. Long-term efficacy will be assessed 6 and 12 months after intervention. Hierarchical regression models will be used to analyze effects over time. DISCUSSION: While there is scientific evidence for the efficacy of education programs addressed to (diabetes) patients, there is a research gap with regard to intervention studies evaluating the efficacy of education programs designed for patients' relatives. The study results will provide information on the efficacy of the DiaLife education program. In addition, factors that might hinder a successful implementation of an education program for relatives will be identified. TRIAL REGISTRATION: German Clinical Trials Register, DRKS00015157 . Registered on 24 August 2018.
引用
- Bernard M, Müller N, Hecht L, et al. Efficacy of DiaLife, an education program for relatives of adult patients with diabetes - study protocol of a cluster randomized controlled trial. Trials. 2019. PMID: 31439049. doi:10.1186/s13063-019-3600-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。